Lexeo Therapeutics’ LX2020 Gains RMAT Designation
FDA granted Regenerative Medicine Advanced Therapy designation to LX2020, Lexeo Therapeutics’ systemic AAVrh10 gene therapy for plakophilin-2-associated arrhythmogenic cardiomyopathy. The designation was based on recent interim data from the ongoing Phase 1/II HEROIC-PKP2 study….
